Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression

Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression

<p>Table S2</p>

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Yun-Guang Hong (14960966) (author)
Andere auteurs:	Zhigang Yang (14960969) (author), Yan Chen (14960972) (author), Tian Liu (14960975) (author), Yuyuan Zheng (14960978) (author), Chun Zhou (14960981) (author), Guo-Cai Wu (14960984) (author), Yinhui Chen (14960987) (author), Juan Xia (14960990) (author), Ruiting Wen (14960993) (author), Wenxin Liu (14960996) (author), Yi Zhao (14960999) (author), Jin Chen (14961002) (author), Xiangwei Gao (14961005) (author), Zhanghui Chen (14961008) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Cancer Biology Molecular and Cellular Biology Therapeutic Research and Development Drug Targets Oncoprotein & tumor suppressor drug targets Gene Regulation Posttranscriptional and translational control Hematological Cancers Leukemias Oncogenes & Tumor Suppressors
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
door: Yun-Guang Hong (14960966)
Gepubliceerd in: (2025)

Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
door: Yun-Guang Hong (14960966)
Gepubliceerd in: (2025)

Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
door: Yun-Guang Hong (14960966)
Gepubliceerd in: (2025)

Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
door: Yun-Guang Hong (14960966)
Gepubliceerd in: (2025)

Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
door: Yun-Guang Hong (14960966)
Gepubliceerd in: (2025)

Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
door: Amir T. Fathi (15313195)
Gepubliceerd in: (2025)

Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
door: Amir T. Fathi (15313195)
Gepubliceerd in: (2025)

Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
door: Ana Vujovic (15207479)
Gepubliceerd in: (2025)

Supplementary Table S2 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
door: Ana Vujovic (15207479)
Gepubliceerd in: (2025)

Supplementary Table S3 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
door: Ana Vujovic (15207479)
Gepubliceerd in: (2025)

Supplementary Table S4 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
door: Ana Vujovic (15207479)
Gepubliceerd in: (2025)

Supplementary Table S5 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
door: Ana Vujovic (15207479)
Gepubliceerd in: (2025)

Supplementary Table S6 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
door: Ana Vujovic (15207479)
Gepubliceerd in: (2025)

Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
door: Ana Vujovic (15207479)
Gepubliceerd in: (2025)

Supplementary Table S8 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
door: Ana Vujovic (15207479)
Gepubliceerd in: (2025)

Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
door: Ana Vujovic (15207479)
Gepubliceerd in: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
door: Long Jiang (14956159)
Gepubliceerd in: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
door: Long Jiang (14956159)
Gepubliceerd in: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
door: Long Jiang (14956159)
Gepubliceerd in: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
door: Yuanqing Ma (15052437)
Gepubliceerd in: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
door: Yuanqing Ma (15052437)
Gepubliceerd in: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
door: Yuanqing Ma (15052437)
Gepubliceerd in: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
door: Yuanqing Ma (15052437)
Gepubliceerd in: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
door: Yuanqing Ma (15052437)
Gepubliceerd in: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
door: Yuanqing Ma (15052437)
Gepubliceerd in: (2025)

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
door: Yuanqing Ma (15052437)
Gepubliceerd in: (2025)

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
door: Yuanqing Ma (15052437)
Gepubliceerd in: (2025)

Supplementary Tables S1-14 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
door: Smruthy Sivakumar (15053536)
Gepubliceerd in: (2025)

Supplementary Tables from Targeting BCL6 in Gastrointestinal Stromal Tumor Promotes p53-Mediated Apoptosis to Enhance the Antitumor Activity of Imatinib
door: Xiangyu Zeng (17314920)
Gepubliceerd in: (2025)

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
door: Zev A. Wainberg (15047031)
Gepubliceerd in: (2025)

Figure S1 from Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR
door: Jeffrey D. Mandell (14963909)
Gepubliceerd in: (2025)

Figure S1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
door: Nicolas A. Giraldo (15050937)
Gepubliceerd in: (2025)

Figure s2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
door: Nicolas A. Giraldo (15050937)
Gepubliceerd in: (2025)

Supplementary Data 1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
door: Nicolas A. Giraldo (15050937)
Gepubliceerd in: (2025)

Supplementary Data 2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
door: Nicolas A. Giraldo (15050937)
Gepubliceerd in: (2025)

Supplementary Data 3 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
door: Nicolas A. Giraldo (15050937)
Gepubliceerd in: (2025)

Supplementary Data1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
door: Nicolas A. Giraldo (15050937)
Gepubliceerd in: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
door: Yufang Bao (15386826)
Gepubliceerd in: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
door: Yufang Bao (15386826)
Gepubliceerd in: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
door: Yufang Bao (15386826)
Gepubliceerd in: (2025)

Cannot write session to /tmp/vufind_sessions/sess_i167jb3gqkoog9lqlvnmuin7f9